A recent study by the Rand Corporation indicated that methamphetamine (MA) abuse costs the United States over $20-$60 billion/year. About 10 million Americans have used MA at least once. Chronic MA use has far reaching health consequences and a tremendous societal impact. At V.A. Medical Centers MA abuse is associated with increased use of facility resources and deleterious consequences for veterans, such as additional psychiatric disorders. There are currently no approved medications for treatment of MA addiction, and consequently there is an urgent need to discover MA pharmacotherapies. Recently the trace amine-associated receptor 1 (TAAR1) has been identified as a target for MA and its analogues, but not for cocaine. Therefore, TAAR1 is possibly a unique MA target. TAAR1 knockout (KO) mice show increased activity in response to MA and we have shown that they preferentially consume more MA as compared to their wild-type (wt) littermates. Additionally, KO mice, and mice expressing a non-functional TAAR1 are insensitive to the aversive effects of MA (hypothermia, conditioned taste aversion). There are no commercially available selective agonists or antagonists for the TAAR1. Developing new drugs that interfere with MA-mediated effects at TAAR1 has clinical implications in that (partial) agonists could serve as treatments to possibly limit MA intake. Conversely, TAAR1 antagonists can serve as important pharmacological tools to further study of TAAR1-mediated physiology. This project will use a translational approach to characterize cultured cells that express multiple non- synonymous single nucleotide polymorphisms (SNP) of human TAAR1. In addition, we will use viral-mediated gene transfer of human TAAR1 polymorphisms in mice to determine the effects of synthesized novel agents designed to both affect human TAAR1 function and to compete pharmacologically with MA. Results from these experiments will identify the role of TAAR1 in MA-mediated pharmacology and behaviors and will characterize potential new pharmacotherapies, synthesized in our laboratories, which can be used to treat specific symptoms of MA abuse and addiction.

Public Health Relevance

Methamphetamine abuse and addiction are significant problems in the VA patient population and this interferes with diagnosis and treatment of other psychiatric disorders. Additionally, VA patients who abuse methamphetamine use VA resources at disproportionate levels. Currently, there are no approved pharmacological treatments for symptoms of methamphetamine abuse. This application will use a translational approach (human genes expressed in cultured cells and mice) to characterize a newly identified MA receptor target and interactions of a new class of synthesized drugs that could provide pharmacotherapies for symptoms of methamphetamine-induced behaviors.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
5I01BX002758-03
Application #
9519702
Study Section
Neurobiology A (NURA)
Project Start
2016-01-01
Project End
2019-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Portland VA Medical Center
Department
Type
DUNS #
089461255
City
Portland
State
OR
Country
United States
Zip Code
97239
Eshleman, Amy J; Nagarajan, Shanthi; Wolfrum, Katherine M et al. (2018) Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (Berl) :
Provencher, Brian A; Eshleman, Amy J; Johnson, Robert A et al. (2018) Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter. J Med Chem 61:9121-9131
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27-34
Tosh, Dilip K; Ciancetta, Antonella; Mannes, Philip et al. (2018) Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega 3:12658-12678
Eastwood, Emily C; Eshleman, Amy J; Janowsky, Aaron et al. (2018) Verification of a genetic locus for methamphetamine intake and the impact of morphine. Mamm Genome 29:260-272
Baladi, Michelle G; Forster, Michael J; Gatch, Michael B et al. (2018) Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther 366:367-376
Tosh, Dilip K; Janowsky, Aaron; Eshleman, Amy J et al. (2017) Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters. J Med Chem 60:3109-3123
Miner, Nicholas B; Elmore, Josh S; Baumann, Michael H et al. (2017) Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity. Neurotoxicology 63:57-69
Miner, Nicholas B; O'Callaghan, James P; Phillips, Tamara J et al. (2017) The combined effects of 3,4-methylenedioxymethamphetamine (MDMA) and selected substituted methcathinones on measures of neurotoxicity. Neurotoxicol Teratol 61:74-81
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2017) Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release. J Pharmacol Exp Ther 360:33-47

Showing the most recent 10 out of 15 publications